www.archive-org-2013.com » ORG » H » HAIWEB

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".

    Archived pages: 58 . Archive date: 2013-12.

  • Title: ++ Health Action International ++
    Descriptive info: .. Search.. www.. haiweb.. org.. Health Action International.. HAI Global.. Overtoom 60/II.. 1054 HK Amsterdam.. The Netherlands.. Tel: +31 20 412 4523.. Fax: +31 20 685 5002.. e-mail:.. info@haiweb.. HAI Europe.. Tel: + 31 20 683 3684.. info@haieurope.. Website:.. haieurope.. HAI Constitution (English).. HAI Constitution (Dutch).. Governance Organigramme.. Mission Statement.. Financial Statements 2012.. HAI Annual Report 2011.. Financial Statements 2011.. Financial Statements 2010.. HAI Global Annual Report 2009.. Financial Statements 2009.. HAI Global Annual Report 2008.. Financial Statements 2008.. HAI Annual Report 2007.. Financial Statements 2007.. HAI Global Annual Report part One.. HAI Global Annual Report part Two.. Annual Accounts (2006).. Member Organisations.. List of Donors.. Complaints [.. NL.. ] [.. EN.. ES.. ].. Acknowledgements.. Some publications on this website arise from the Developing Rational Use of Medicines in Europe project, which has received funding from the European Union, in the framework of the Health programme.. The views expressed in these publications are those of the authors, who are solely responsible for the content.. The Executive Agency for Health and Consumers is not responsible for any use of the information herein.. Health Action International (HAI).. Stichting Health Action International is a Dutch civil society Non-Government Organisation (NGO), with a coordinating office (HAI Global) in Amsterdam and partner regional offices Africa (Nairobi), Asia Pacific (Penang), Latin America (Lima) and Europe (Amsterdam).. Although primarily a Dutch organization, HAI is recognised for its global medicines policy expertise and as a non-profit, independent, worldwide network of over 200 members including consumer groups, public interest NGOs, health care providers, academics, media and individuals in more than 70 countries.. Core HAI Documents for Download.. 'Measuring medicine prices, availability, affordability and price components 2nd edition'.. In May 2008 Health Action International (HAI) and the World Health Organization (Department of Medicine Policy and Standards) published the 2nd edition of a manual to collect and analyse medicine prices (patient prices and government procurement prices) across sectors and regions in a country, as well as medicine availability, treatment affordability and all price components in the supply chain from manufacturer to patient (taxes, mark-ups etc.. ).. Governments, civil society groups and others concerned about the prices of medicines are encouraged to undertake a survey using the methodology outlined in the manual.. Download in English, French, Spanish and Russian on this page.. 'Understanding and responding to pharmaceutical promotion: A practical guide'.. Pharmaceutical promotion influences how doctors and pharmacists choose to prescribe and dispense medicines.. These decisions may lead to sub-optimal treatment choices that damage public health and escalate health care costs.. Although the influence of pharmaceutical promotion starts early in medical and pharmacy students training, these students receive little to no instruction on how to assess promotion.. To address this need, HAI and WHO published a manual that medicine and pharmacy schools can use to train students how to recognise and respond to pharmaceutical promotion before they start prescribing and dispensing medicines.. This educational tool enables students to critically analyse pharmaceutical promotion and access higher-quality, unbiased and independent information about medicines.. Download the manual in.. English.. ,.. French.. Spanish.. or.. Russian.. Instructors and students that have used the manual in class are encouraged to download and submit an evaluation form in.. 'Assess the nature and extent of countries' pharmaceutical promotion control and its impact on promotional practices'.. Many countries either rely on the pharmaceutical industry to self-regulate promotional activities through voluntary codes of practice or have introduced a legislative framework.. With the support of the Medicines Transparency Alliance (MeTA), HAI has developed an innovative methodology to assess the nature and extent of countries' pharmaceutical promotion control and its impact on promotional practices.. HAI's methodology combines desk research, interviews and data collection to provide a complete profile of the national situation, highlighting the strengths and weaknesses of the regulatory framework and provide analysis of stakeholder positions.. Download in.. English (PDF 730 Kb).. Medicines for Non-Communicable Diseases: Within our Grasp but Out-of-Reach.. Reliable, accessible, potentially cheap and effective treatments with generic medicines for the majority of non-communicable diseases (NCDs) such as cardiovascular disease, diabetes and asthma are within our grasp.. But low availability, and high prices of originator brands and even some lowest-priced generics, put them out-of-reach of the majority of the world s poor.. HAI calls on delegates at the UN High Level Meeting on NCDs on 19/20 September 2011 in New York to refocus on the attainable goal of universal access to essential medicines as a core priority for the treatment of NCDs.. Donors need to recognise the paucity of support for essential medicines initiatives, globally, regionally and nationally, such as those by WHO, civil society and governments.. In the longer term, donors should consider scaling-up support to establish a Global Fund for Essential Medicines for Non-Communicable Diseases that promotes universal access to low-priced generic medicines of assured quality.. Click here.. to read HAI's briefing note on access to medicines for non-communicable diseases.. Reviews of pricing policies and interventions now published.. Substantial opportunities exist to increase medicine availability, reduce prices, and improve the affordability of medicines in all regions of the world and at all levels of economic development.. However, it can be challenging to identify and prepare suitable lines of response.. To assist policy-makers and others, WHO and HAI are developing a series of reviews on pharmaceutical pricing policies and interventions, with a focus on low- and middle-income countries.. Five reviews have now been published on:.. External Reference Pricing.. The Role of Health Insurance in the Cost-Effective Use of Medicines.. The Regulation of Mark-ups in the Pharmaceutical Supply Chain.. Competition Policy.. Sales Taxes on Medicines.. Another four reviews are in development, including a review on promoting the use of generic medicines.. To access the papers.. click here.. Anti-competitive strategies hamper access to medicines in Europe.. HAI Europe s concerns about unfair competition in the EU s pharma sector are published in The Amsterdam Law Forum.. The anti-competitive strategies outlined in this article can artificially extend the market dominance of a best-selling originator medicine, delaying generic entry and prolonging company profits at the expense of widespread access.. This article examines how governments could guarantee access to high quality, safe and effective medicines by ensuring fair and effective competition on the EU s pharmaceutical market.. Continue reading.. HAI Europe s article published on 2 February 2011 in the online journal The Amsterdam Law Forum.. Corporate sponsorship linked to EU patient and consumer groups policy perspectives.. HAI Europe's latest research has established a link between patient and consumer groups perspectives on EU medicines policies and the funding they receive from the pharmaceutical industry.. Worryingly, these findings highlight the potential for the erosion of the patient and consumer voice in pharmaceutical policy debates at the European level.. Continue reading the.. Press Release.. 31 January 2011 - HAI Europe Research Article.. The patient consumer voice and pharmaceutical industry sponsorship.. Written by Katrina Perehudoff and Teresa Leonardo Alves.. 31 January 2011 - HAI Europe Factsheet.. Can We Afford the Current Model of Medical Innovation?.. Towards New Models of Innovation.. Thursday, 18 November 2010, 09:00 13:50.. Room (TBC), European Parliament, Brussels.. Hosts.. Thijs Berman MEP, Progressive Alliance of Socialists Democrats.. Eva Joly MEP, The Greens/EFA.. Carl Schlyter MEP, The Greens /EFA and on behalf of the.. European Parliament Working Group on Innovation, Access to Medicines and Poverty-Related Diseases.. Conference program and concept note.. To register for this event, please complete and return.. this registration form.. by e-mail to Marine Avrillon at.. marine@haieurope.. HAI Europe reveals new data on financial transparency of patient and consumer organisations.. 11 August 2010 - HAI Europe Research Article.. Patient Consumer Organisations at the EMA: Financial Disclosure Transparency.. Written by Katrina Perehudoff and Teresa Leonardo Alves.. 11 August 2010 - HAI Europe Factsheet.. Health Action International at the 63rd World Health Assembly.. Press release.. 22 May 2010, Geneva- This years World Health Assembly (WHA) was historic.. Health Action International (HAI) followed some of the most controversial issues that were up for discussion on this ambitious agenda: the debates and action around agenda items 11.. 3 Global Strategy and Plan of Action (GSPA) on Public Health Innovation and Intellectual Property, and 11.. 20 Counterfeit Medical Products.. On both issues, the debate played out more or less with opposing positions taken by Northern and Southern countries.. Read more.. Interventions.. 19 May 2010, Geneva - As HAI is an NGO in official relations with the World Health Organization, we took the opportunity to submit two NGO intervention texts for consideration at the WHA.. However, unfortunately HAI was not able to deliver either of the interventions during the Committee sessions.. Please click on the following links to see the submissions on the.. Global Strategy and Plan of Action (GSPA) on Public Health Innovation and Intellectual Property.. and.. Counterfeit Medical Products.. HAI Global Statement.. Civil society freedoms endangered by anonymous threats:.. Stifling debate about public health in the H1N1 pandemic.. 11 May 2010 - Health Action International (HAI) Global firmly supports freedom of expression and the freedom of civil society to carry out their work uninhibited by threats or intimidation.. We are deeply troubled by the anonymous threats made against the Coordinator of our network partner, AIS (HAI) Bolivia following public statements about the H1N1 influenza vaccine debate.. Global pill price snapshot reveals large differences in the price of ciprofloxacin.. On 30 November 2009, individuals from Health Action International s extended network carried out a snapshot survey of the price that patients have to pay for ciprofloxacin, a commonly used off-patent antibiotic, in their nearest private retail pharmacy.. To follow up the survey, HAI Global developed an.. interactive map.. available at.. http://www.. org/medicineprices/.. to show the cost of a course of ciprofloxacin (14 tabs; in US$), for both the originator brand and lowest priced generic in the 93 countries that were surveyed.. This map, along with all the survey results went live on Monday 11 January 2010.. On the website you can also access a four-page briefing note, which includes an analysis of the results and recommendations.. This briefing note is available in English, French, Spanish and Russian.. Briefing notes with results from geographic regions are also available.. To download the press release, click on this link.. org/medicineprices/05012010/PressRelease.. pdf.. Statement.. HAI Europe is granted full membership by the European Medicines Agency.. 24 March 2010 Health Action International (HAI) Europe has been closely monitoring the European Medicines Agency's policies and developments for several years.. The HAI network has frequently contributed to EMA consultations, played a role in reviewing medicines information for the public, and championed the interests of European citizens and public health in medicines policy.. Final Report:.. Impact of the EU-Andean Trade Agreements on Access to Medicines in Peru.. 11 November 20009 - This study carried out by the IFARMA foundation in Colombia was commissioned by the EU-CAN Alliance for Access to Medicines and has now been published by HAI Europe.. The study evaluates the potential impact on access to medicines in Peru from the intellectual property measures proposed by the European Union as part of the trade agreement being negotiated between the EU and some Andean countries.. It specifically assesses the impact of increasing the effective duration of pharmaceutical patents and test data protection, as proposed by the EU in February 2009.. Download here.. Full report in Spanish.. HAI Europe Open Seminar 23 October 2009 Brussels.. EU Policy in Action: In whose Interests?.. There is often a divergence between policy and action in political decision-making.. In order to assess the effectiveness of policies, it is essential to understand how and why decisions are made in reality.. Medicines policy in the European Union represents a prime example of such divergence and HAI Europe s campaigns have sought to research and analyse areas of incoherence in order to present policy recommendations that ensure EU policies match its actions.. This year s HAI Europe Open Seminar examined the European Union s policies and actions in relation to medicines and provide an opportunity for stakeholders to publicly debate their views.. The event included two panels:.. Panel 1: Unwrapping the Pharma Package: What s in it for Consumers?.. This panel looked at two of the main components of the Pharmaceuticals package, the Information to patients directive and the Pharmacovigilance directive.. The panel also discussed the roles played by various EU decision-making bodies and stakeholders in the development and negotiation of the Pharmaceuticals package.. Panel 2: Trading Away Access to Medicines..  ...   pharmaceuticals market is not working well: lack of innovative medicines being brought into the market, and delays in the registration and commercialization of generics.. The inquiry will investigate the factors contributing to the current situation.. The commission suspects that the companies in question, either by misusing patent rights or recurring to vexatious litigation and other means, have made it extremely difficult for other generic manufacturers to enter the European market.. HAI Europe welcomes the move taken by the Commission in defending consumer and patient rights and hopes that the results of the enquiry will lead towards ensuring equitable access to essential medicines within the European Region.. Children's medicines.. HAI welcomes the overriding aim of the selection of essential medicines for children as a contribution to the improvement of global public health, specifically in children.. However, the selection of essential medicines for children outlined in the un-edited report of the first meeting of the subcommittee of the Expert Committee on the Selection and Use of Essential Medicines raises some concerns.. Click on here to read more.. Governments drive R&D to meet real health needs changes in sight?.. Amsterdam 10 November 2007 The World Health Organisation (WHO) Intergovernmental Working Group for Public Health, Innovation and International Property (IGWG) has met over the past week in Geneva.. The group, convened to discuss improved medicines research and development for the world s poor countries, agreed on basic principles for a Global Strategy and Action Plan.. For more information, please read the.. press release.. Time to say "No thanks"?.. Family physicians have the right and the obligation to receive their education and information in an environment free from the influence of marketing strategists.. A recent article published in the Canadian Family Physician outlines the pitfalls involved in the medical world s reliance on funding of continued medical education by the pharmaceutical industry.. Article:.. cfp.. ca/cgi/content/full/53/10/1635.. Bibliographie:.. ca/cgi/content/full/53/10/1635/DC1.. Rational Use of Medicines: back on track.. On 18 May 2007, the 60th WHA approved the Resolution on Rational Use of Medicines.. This resolution calls for an integrated health-systems approach to the rational use of medicines and urges Member States to set a national body aimed at monitoring and promoting the rational use of medicines.. In addition, it advocates for a multidisciplinary approach among interested parties, as well as the engagement of civil society.. Most notably, it urges Member States to enact and enforce legislation to ban unethical drug promotion, as well as calling for governments to work on the provision of independent information.. HAI has been involved in the writing up of this resolution since its inception.. We have also lobbied actively for its approval, as we recognize that there is a lot to be done in what concerns the rational use of medicines.. The foundation has now been laid for future work in this field and we shall be looking forward to the rolling out and implementation of the resolution.. As a preparatory activity, HAI organized, jointly with WHO, EPN and ReAct a briefing on 15 May entitled Saving lives, Saving money, achieving the rational use of medicines.. The event was well attended and highlighted the importance of the resolution being proposed and its potential impact on health outcomes.. The presentations from that briefing are.. now available here.. For the resolution,.. For the report on the Progress in the rational use of medicines,.. HAI at the 60th World Health Assembly.. HAI is pleased to support the Rational Use of Medicines (RUM) Resolution at the forthcoming World Health Assembly in Geneva.. In partnership with the WHO, the Ecumenical Pharmaceutical Network, and ReAct, HAI has produced a.. Briefing Paper.. for distribution at the WHA, and will be participants in the Briefing Session on Tuesday 15 May.. The programme for this session is available.. here.. as well as.. the accompanying poster.. HAI Response to EU Consultation on Patient Health Information:.. No role for industry in disease and comparative treatment information.. The European Commission has just carried out a consultation on two reports produced by the Pharmaceutical Forum s Working Group on Patient Information.. These include model patient information on diabetes and a set of information quality criteria.. The Pharmaceutical Forum is heavily dominated by the pharmaceutical industry, and a key aim of this initiative is to involve industry in providing disease and treatment information to the public paving the way for direct-to-consumer advertising.. HAI-Europe s response stresses that the pharmaceutical industry has no role in providing the public with comparative treatment information, or information on disease epidemiology or prognosis because of inherent conflicts of interest.. It also raises concerns about the legitimacy of this process.. Read our full response here.. HAI Europe Conference 2006.. HAI Europe thanks all those who helped to celebrate its 25th Anniversary by attending the special jubilee conference Pills, Politics and Practice in Amsterdam on 26-27th October 2006 (.. For programme click here.. ).. The report on the conference proceedings can now be downloaded by.. clicking here.. These proceedings give further links to the speakers biographies.. For an overview of those who registered participation at the conference please.. If you would like to obtain a copy of the special conference publication Pills, Politics and Practice which was distributed to all participants during the conference and which featured some of the people who have made HAI a leading NGO worldwide on pharmaceutical policy issues, then please contact the HAI Europe secretary, Rose de Groot, on.. rose@haiweb.. Educating medical and pharmacy students about drug promotion.. An editorial in the November 2006 issue of the open-access journal PloS Medicine highlights the need to educate health professionals about drug and device medicine and provides key recommendations for how this education should be carried out.. Four groups are involved in this call to action: the American Medical Students Association, Healthy Skepticism, No Free Lunch and PharmAware.. See full article.. HAI-Europe and WHO are jointly collaborating on a project, together with an international team of educators, to develop and field test an educational manual for medical and pharmacy students on drug promotion.. A global survey of educational initiatives carried out as part of this project describes the work of 228 educators from 64 countries.. There are many individual initiatives to educate students about the influence of drug promotion on professional practice, but they remain marginal in most cases to core curricula, with students in most cases devoting one half day or less to this topic during their professional training.. See full survey report.. EMEA implementation of transparency regulations called into question.. 11th October 2006 A broad definition of commercial confidentiality is the key barrier to public access to information on the safety and effectiveness of medicines, leaving European citizens at greater risk for otherwise preventable harm.. HAI Europe responds to EU Pharmaceutical Forum initiative: is this advertising disguised as health information?.. Health Action International Europe (HAI-E), the International Society of Drug Bulletins (ISDB), the Association Internationale de la Mutualité (AIM), the Bureau Européen des Unions de Consommateurs (BEUC), and the Medicines in Europe Forum (MiEF) have endorsed a joint declaration on the provision of relevant health information to citizens, to be presented on the occasion of the meeting of the European s Commission Pharmaceutical Forum.. Considering that health information is a fundamental and necessary part of healthcare, the organisations call for a clear distinction between information and advertising disguised as information.. They warn of the inherent conflicts of interest of pharmaceutical companies which are unable to provide unbiased comparative information on available drug and non-drug treatment alternatives.. download the declaration.. HIV/AIDS Universal Access by 2010.. ten challenges on the way.. If universal access to antiretroviral therapy (ART) by 2010 is to be achieved, all those engaged in implementation - at every level - must address challenges.. HAI has developed a policy brief which highlights 10 challenges on the way to achieving universal access to ART by 2010.. Healthworkers, policy makers and ART users from 14 countries identified these challenges during rapid appraisal assessments conducted by HAI, the International Treatment Preparedness Coalition (ITPC) and the University of Amsterdam.. Read the brief.. Now in Spanish: Acceso Universal para el 2010 10 retos en el camino.. Report from the HAI Seminar on Risk communication with patients.. This seminar was a by-product of HAI Europe s participation in the Working Group with Patients and Consumers Groups in the European Medicines Agency (EMEA).. One area of work of this Working Group is Pharmacovigilance, information and communication about safety issues, Adverse Drug Reactions (ADR) of medicines and reporting systems for ADR.. The issue of communication with the public and patients about the positive and negative effects of medicines involves both patients and consumers groups and so HAI Europe arranged an additional seminar in London for the members of this Working Group who came together for the EMEA meeting.. Read more.. HAI supports the Rational Use of Medicine at the WHA Executive Board.. A small HAI team stayed on after the WHA to lobby members of the Executive Board in support of the WHO secretariat's proposed resolution on the Rational Use of Medicines (RUM) last week.. HAI welcomes the decision of the EB to revisit the resolution next year before it goes forward to the World Health Assembly.. However, whilst the resolution passed by the EB re-establishes the Rational Use of Medicines as a core agenda item, the resolution could go much further.. Read the press release and HAI's intervention to the Executive Board here.. Press Release re R&D Resolution at 59th WHA.. Health Action International (HAI) applauds the decision of the World Health Assembly (WHA) to pass a resolution which calls on governments to act to boost innovative research and development (R&D) of medicines.. The passing of this resolution indicates that governments recognize the crisis in R&D and the failure of current systems to effectively address health needs in developing countries.. The resolution builds on the findings of the Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH)) report and acknowledges the need for immediate action.. For full text of Press Release.. Pharmacovigilance in the EU.. Recent high-profile drug withdrawals, such as Vioxx and Lipobay, have rightly proved to sharpened public interest in the European system of pharmacovigilance.. Moreover, the tendency towards the direct promotion of medicines to consumers (especially via the internet), the limited amount of clinical trial data available to the general public, shorter approval times and the switching of prescription only medicines to over-the-counter, all add up to the need for robust post-marketing surveillance.. It is therefore timely and appropriate that HAI is pleased to engage with the European Commission s (DG Enterprise) consultation on pharmacovigilance in the EU, which we argue is flawed, and certainly cannot offer the robust and responsive system that European citizens might expect, need and vote for.. Read our full response here.. CIPIH Report could change the lives of neglected patients.. HAI is encouraged by the clear assertion in the report of the need for people oriented approaches to health policy, and that application of intellectual property rules should take account of the circumstances in which they were being used.. 'Real people and not realpolitik should be the central emphasis' stated Dr.. Kumuriah Balasubramaniam, Regional Coordinator of the Asia-Pacific Office.. Global AIDS Alliance Responds to WHO Report on Treatment Access.. read more.. Survey shows some students only get 1-2 hours education about drug promotion during professional training.. Education of medical and pharmacy students plays a crucial role in preparing future practitioners to respond appropriately to drug promotion.. But a survey of medical and pharmacy schools, conducted by HAI and WHO in 2005, found that while most respondents included education on promotion in the required curriculum, a half a day or less was devoted to this important issue during the students professional training.. In nearly one-third of cases, medical schools devoted only 1-2 hours often within a broader course on pharmacology, clinical pharmacology or therapeutics.. Few students are taught how to respond to patient requests for advertised drugs despite direct-to-consumer advertising of prescription drugs and other promotional techniques targeting the public becoming more prevalent.. These are some of the key findings in the survey report.. Educational initiatives for medical and pharmacy students about drug promotion: an international cross-sectional survey.. by Barbara Mintzes.. Disclaimer.. © Copyright St.. Health Action International Foundation (HAI).. Medicine Prices.. Essential Innovation.. and.. Intellectual Property.. Drug Promotion.. Public Private Interactions.. Conflict of interest..

    Original link path: /
    Open archive

  • Title: ++ Health Action International Europe ++ [ Focus ]
    Descriptive info: Introduction.. WHO.. HAI position.. HAI Europe members working on Health, Innovation and Access.. I+A Platform.. In high-income countries a market-driven pharmaceutical industry does not always sufficiently respond to the needs of particular patient groups, such as women and children.. In addition, across the world, it excludes those population groups who represent commercially non-viable medical needs, despite the fact that their illnesses account for a significantly large proportion of the global health burden.. The commercial power and influence of the pharmaceutical industry in national and global healthcare policy has thrown up a visible divide between trade competitiveness and public health.. Increasingly public health appears to be sacrificed in the race between regions for trade superiority.. Health care systems are under enormous strain, and costs continue to spiral, without clear signs of benefits for the public.. Yet it is the public that pays for innovation in health through a number of mechanisms such as taxes, corporate tax breaks and credits, health insurance schemes, and through legal frameworks such as patents.. As need-driven health research is becoming increasingly important: WHO is developing a global strategy and plan of action, and HAI members all over the world are actively working on a future scenario: Where the market fails, new approaches to pharmaceutical R&D are called for.. 28 November 2008.. Event Memo DG Competition s Presentation of its Preliminary Report into the Pharma Sector.. 31 January 2009 -.. HAI Europe s response to DG Competition interim report on Pharmaceutical Sector Inquiry Jan 31.. 17 February 2009 - Read Health Action International s response to the Guardian article, Drug giant pledges cheap medicine for the world's poor,.. guardian.. co.. uk/world/2009/feb/17/gsk-stop-aids-campaign.. 31 March 2009 Publication -.. Advanced Market Commitments: Current Realities and Alternate Approaches.. by Professor Donald W.. Light, University of Medicine and Dentistry of New Jersey, USA.. Published by Health Action International and Medico International.. See press release.. 15 April 2009 -.. HAI Response to the Expert Working Group on Alternative Financing.. 10 August 2009 -.. HAI Europe Statement on DG Competition s final report on pharmaceutical sector Inquiry.. 4 September 2009.. HAI Response to Second Public Consultation from the Expert Working Group on Research & Development Financing.. 15 January 2010 -.. Open letter to WHO Executive Board on EWG GSPA implementation.. (.. ).. 19 January 2010 -.. HAI Global Statement at WHO Exec Board on EWG report.. 20 January 2010 -.. Event Memo 126th WHO Exec Board Agenda item on EWG presentation.. 11 May 2010 -.. Joint TWN HAI Statement WHO should refocus its efforts.. 17 May 2010 -.. HAI Intervention on Agenda Item 11-3 Public health innovation and IP.. 19 May 2010 -.. HAI Intervention on Agenda Item 11-20 Counterfeit Medical Products.. 22 May 2010 -.. Press release 63rd World Health Assembly (2).. 18 November 2010 -.. Can We Afford the Current Model of Medical Innovation? Towards New Models of Innovation.. On the 18th of November HAI together with partners TACD, Oxfam en KEI organised a conference on the need for new models of innovation in the European Parliament.. Concept Note Innovation and Access Conference at EP.. 29 November 2010 -.. Joint Statement Increasing calls within EU for new models of medical innovation.. 29 November 2010 -.. Event Memo Can We Afford the Current Model of Medical Innovation EP meeting.. TRADE AGENDA AND ACCESS TO MEDICINES.. 25 October 2010 -.. Policy brief on ACTA and Access to Medicines.. 1 December 2009 -.. HAI Europe response to the European Commission s Global Health consultation.. 11 Janaury 2010 -.. Open Letter to Commissioner de Gucht on Joint Declaration.. 11 January 2010 -.. Joint Declaration Trading Away Access.. 19 February 2010 -.. Press release prioritise and protect Access to medicines in Central America.. 22 March 2010 -.. HAI Europe response to the DG Trade Consultation on ACTA.. 26 April 2010 -.. Compulsory licenses in Ecuador.. 27 April 2010 -.. EU-India FTA poses a serious threat.. 29 July 2010 -.. Joint Open letter on ACTA to DG Trade Commissioner de Gucht from HAI Europe, Oxfam, Knowledge Ecology International, Public Citizen and Vrijschrift.. 29 July 2010:.. Joint civil society letter on ACTA and Access to Medicines to Trade Commissioner de Gucht.. Intellectual property enforcement initiatives threaten consumer rights and public health.. 12 June 2009 - The TransAtlantic Consumer Dialogue (TACD), Health Action International (HAI) and Knowledge Ecology International (KEI) hosted a public meeting on the issue of intellectual property rights enforcement in Brussels on Wednesday, June 10th.. Click here for joint press release.. HAI Members'Comment on Anti-Counterfeiting Trade Agreement.. 3 July 2009 - Health Action International (HAI) members in Canada have contributed  ...   European and Andean Association Agreement.. by Xavier Seuba Hernandez.. also available in Spanish.. Executive Summary and Conclusions.. 24 March 2009 -.. Highlights from the Peru and Colombia Impact Studies: EU Intellectual Property proposals.. presented during the negotiation rounds in Lima.. 23 April 2009 Open letter -.. EU-CAN Alliance to the European Council.. on the negotiations round 4-9 May 2009 in Brussels.. Annex 1.. on the public health concerns with the intellectual property chapter in the trade agreements and.. Annex 2.. 1 May 2009 -.. Summary of Preliminary Results Peru Colombia Impact Studies.. 1 May 2009 Policy Brief -.. Protecting Access to Medicines in EU Trade Agreements: The Andean Region.. 6 May 2009 Press release.. - EU's Intellectual Property agenda could impair access to medicines in the Andean region.. 16 June 2009 Press release -.. EU Commission pushes its trade agenda on Andean nations despite public health consequences.. 20 July 2009 - Press release -.. EU negotiators are trading away Access to Medicines in Andean countries.. - Following the round of trade negotiations between the European Union and Peru and Colombia in Lima, Peru, the CAN-EU Alliance of European and Andean civil society organisations is calling on the EU to abandon all TRIPS plus demands in order to protect access to medicines for the Andean populations.. 11 November 2009 -.. Final Report: Impact of the EU-Andean Trade Agreements on Access to Medicines in Peru.. Click.. for the full report in Spanish.. 16 December 2009 Presentation -.. Impact of EU Trade Agreements on Access to Medicines.. 29 March 2010.. Impact of the EU-Andean Trade Agreement on Access to Medicines in Colombia.. DUTCH SEIZURES OF GENERIC MEDICINES IN TRANSIT.. The case of the losartan seizure, which became public in January 2009, was a clear demonstration of European enforcement of intellectual property (IP) rights trumping access to medicines.. HAI immediately responded to this news with a.. , highlighting the inconsistency between the EU s uncompromising IP enforcement agenda and commitments made by EU Member States, including the Netherlands, to promote and protect public health in developing countries.. This was followed by a.. joint letter with the Trans Atlantic Consumer Dialogue.. and a.. joint letter from HAI and Oxfam Novib.. to the Dutch Ministries Finance, Economic Affairs, Foreign Affairs, and Health, which called on the authorities to assess and determine conclusively whether the present EU regulations and practices on border measures are consistent with policies for facilitating universal access to medicines.. HAI was also part the group of NGOs that sent letters to the.. WTO.. , demanding that the WHO immediately undertake an assessment of the risks to public health programs presented by such seizures and that the WTO examine whether EU customs rules and provisions in trade agreements present risks to goods in transit, and undermine the commitments made in 2001 in the Doha Declaration on TRIPS and Public Health concerning access to medicines.. HAI then issued a statement.. following, WTO Director-General, Pascal Lamy s response to the NGO letter.. The news at the end of February about the seizure of a UNITAID/Clinton Foundation shipment of ARV medicines brought home the importance of tackling these interventions in the legitimate trade of generic medicines.. HAI issued a.. joint press release.. with Oxfam International and Knowledge Ecology International to condemn this unacceptable seizure of HIV/AIDS medicine that threatened the treatment of HIV positive Nigerians.. Following the recent release of the UNITAID shipment,.. HAI issued a statement.. on 20 March 2009 welcoming the release of these life-saving medicines but urging the authorities to refrain from seizing generics by applying overambitious border measures and allowing IP enforcement measures to distort or corrupt the free movement of legitimate medicines in transit.. At the beginning of April 2009, HAI filed an official request with the Dutch government, under the Wet Openbaar Bestuur (the Dutch-equivalent of a Freedom of Information Act), to release all documents related to the recent seizures of generic medicines in transit (.. click here for the statement.. On 7 May 2009, HAI received the.. Official Response to Freedom of Information request.. which is also available in Dutch.. On 5 May 2009, a shipment of the antibiotic, Amoxicillin, manufactured in India and destined for the Republic of Vanuatu in the Pacific, was seized by customs officials while in transit through Frankfurt, Germany.. Amoxicillin is an essential medicine used to treat a wide range of bacterial infections.. from Health Action International (HAI), Oxfam International, BUKO-pharma, Medico International and Third World Network.. 11 August 2009.. HAI Europe Statement on the latest developments on seizures of generic medicines in-transit.. See.. Literature Review.. -.. Media..

    Original link path: /02_focus_b.htm
    Open archive

  • Title: ++ Health Action International Europe ++ [ Others ]
    Descriptive info: Understanding and responding to pharmaceutical promotion: A practical guide.. These decisions may, however, lead to sub-optimal treatment choices that damage public health and escalate health care costs.. Although the influence of pharmaceutical promotion starts early in medical and pharmacy students’ training, these students receive little to no instruction on how to assess promotion.. To address this need, HAI and WHO published a manual that schools of medicine and pharmacy can use to train students how to recognise and respond to pharmaceutical promotion before they start prescribing and dispensing medicines.. The manual is available free-of-charge and can be downloaded in.. Hard copies of the manual (in English or Spanish) may also be requested by emailing.. manual@haiglobal.. Please note that shipping charges may apply.. Have you taught the manual, or used it as a student? Share your experience with us—and help us improve the next edition—by completing and submitting an evaluation form (.. Español.. Medicines promotion: Assessing the nature, extent and impact of regulation.. Irrational use of medicines results in inappropriate treatment, a waste of resources and increased drug resistance.. As a result, but measure to restrain promotion vary widely in terms of content, penalty and enforcement.. The findings will reveal transferable best practice and provide evidence on which countries can make informed policy choices to protect public health.. More information.. Report and Preliminary Methodology for Pilot-testing.. At the 118th session of the WHO Executive Board turns its attention to the Rational Use of Medicine (RUM) - But does it go far enough?.. Health Action International (HAI) was pleased to support the WHO secretariat’s proposed resolution on the Rational Use of Medicines (RUM) at the 118th Executive Board (EB) meeting last week.. The number of countries who spoke at the EB in support of this resolution showed how important this topic is to all Member States and HAI applauds the commitment of the EB to this crucial area of health policy.. HAI also welcomes the decision of the EB to revisit the resolution next year before it goes forward to the World Health Assembly.. However, whilst the resolution passed by the EB re-establishes Rational Use of Medicines as a core agenda item, the resolution that emerged from the a ’drafting group’ after a number of EB members proposed changes in the text, could go much further.. Among other things, the resolution, in the form that will progress to next years EB in January 2007, urges Member States to invest resources to ensure the appropriate use of medicines and establish national bodies to promote the rational use of medicines (including training programmes for health workers).. Moreover, HAI particularly welcomes that the resolution calls on Member Sates to ’enact new, or enforce existing, legislation to ban inaccurate, misleading or unethical promotion of medicines’.. However, as far as HAI is concerned, one of the main objectives of the Resolution is to provide WHO with a new mandate to provide effective technical support to Member States to implement national coordinated programmes to promote RUM.. (i.. e.. to take a health systems approach to promoting rational use of medicines).. This objective was incorporated in operative paragraph 2.. 2 of the original document which urged the Director General ‘establish mandated multi-disciplinary national bodies to monitor medicine use and to develop national programmes to promote the rational use of medicines’ However, this paragraph was revised and weakened.. The revised paragraph no longer talks of ‘mandated multi-disciplinary national bodies to monitor medicine use and to develop and coordinate ….. national programmes’ which was an articulation of the health systems approach advocated in the report as a whole and the justification for allocation of WHO resources.. ‘Without this paragraph, both budget and mandate will be seriously reduced’ said a WHO source.. Tim Reed, Director of HAI Europe said ‘We are absolutely delighted that Member States are once again placing the Rational Use of Medicines at the core of WHO policy, but disappointed that the resolution stops short of giving the WHO the mandate to do anything more concrete.. Next year we want a final resolution that will give the WHO the mandate and financial means to help Member States in order that we can dramatically reduce the physical harm and waste of resources that the irrational use of medicines produces.. ’.. For further information contact.. Tim@haiweb.. INTERVENTION.. Rational use of medicines: progress in implementing the WHO medicines strategy.. Provisional Agenda Item 5.. 3.. EB118/6.. Chairperson and distinguished Members of the Executive Board.. My name is Tim Reed representing Churches Action in Health and Health  ...   urge the executive board to request the Director-General to strengthen the leadership and advocacy role of the WHO in promoting the rational use of medicines and to facilitate the strengthening of WHO's technical support to Member States in order that they might establish national bodies to monitor medicine use.. Moreover, we suggest that research is conducted with some urgency into sustainable nationwide interventions and the promotion of rational medicine use at all levels of the health sector, both public and private, and to health-care providers, patients and consumers.. Thank you.. Promoting the Rational Use of Medicines.. Pharmaceutical companies compete for product sales and market share, and this has led to an increasing amount of spending on drug promotion aimed at health professionals and the public.. But too often the promotion of drugs overstates the benefits and understates the risks of taking a particular medicine.. Promotion of drugs to consumers.. does not provide them with the reliable and objective information about medicines that they need.. Consumers may be forced to make choices about medicines based on insufficient information about how a medicine performed in trials and how other patients have reacted to taking it.. They may not be able to critically evaluate drug promotion or be aware of the basic principles of rational drug use.. In a major campaign success, EU pharmaceutical legislation passed in April 2004 maintained the ban on advertising prescription-only drugs directly to the public.. But the battle is still to ensure that the information consumers receive is not advertising in disguise.. HAI Europe campaigns for consumers to have access to information that is truly objective.. Unethical drug promotion targeted at health professionals includes misleading presentation by medical representatives, inappropriate inducements and gifts and promotional activities disguised as educational symposia and clinical trials.. Health personnel often have insufficient training to see promotion for what it is and to critically appraise it.. HAI, together with the World Health Organisation (WHO) has produced a.. database of how prescribers and others are influenced by drug promotion.. and is involved in the production of a manual on.. educational initiatives.. to teach medical and pharmacy students skills in appraising promotional approaches by drugs companies.. Drug Promotion: what we know, what we have yet to learn.. Reviews of materials in the WHO/HAI database on drug promotion.. WHO/EDM/PAR/2004.. EDM Research Series no.. 32.. Authors: Pauline Norris, Andrew Herxheimer, Joel Lexchin, Peter Mansfield.. Published by the World Health Organization (WHO) and Health Action International (HAI).. This report is part of a project on drug promotion being carried out by WHO and HAI Europe and collated on a database (www.. drugpromo.. info).. This stage involved collecting and analysing existing information on drug promotion.. Analysis focussed on the impact that drug promotion has on professional and lay people s attitudes to promotion; its impact as a source of drug information; its influence in prescribing habits and public health (funding of research); and the interventions that have been tried to counter promotional activities.. Educational Initiatives for medical and pharmacy students about drug promotion: an international cross-sectional survey.. WHO/PSM/PAR/2005.. 2.. 36.. Author: Barbara Mintzes, October 2005.. Published by the World Health Organization (WHO) and Health Action International (HAI).. Increasing attention is being paid to the relationship between health professionals and the pharmaceutical industry.. This is the first international survey to examine the extent to which medical and pharmacy students are being educated about drug promotion within the required curriculum.. The report shows that although educators found many barriers to success in achieving critical appraisal of promotion, there is a broad interest in further development and work in this area.. HAI s latest document relating to rational use of medicines has been on.. patients reporting of adverse reactions.. , published in July 2005.. Pressure to allow patients to report details of adverse reactions directly to the relevant authorities has developed following a number of cases where the response to users evidence of harm had been slow and inadequate.. As a result, patients reporting systems have recently been established in several European countries.. A seminar organised by Health Action International Europe in Brussels on 26 May brought together those responsible for running these systems, as well as other key experts.. A report of the meeting summarises the lessons that can be derived from early experience with receiving patients reports.. The document urges national and European agencies to be more open to patients reporting and by doing so to show greater respect to those experiencing illness and taking medicines.. Click here to access all the information..

    Original link path: /03_other.htm
    Open archive

  • Title: ++ Health Action International Europe ++ [ Focus ]
    Descriptive info: Growing recognition of the depths and costs of the AIDS crisis have produced, at the transnational level, a shift away from a largely public production of health care policy to an institutional framework involving a mix of actors.. Private Public Interactions (PPIs) are proposed as win-win solutions to the AIDS pandemic.. With an outcome orientation and efficient lean governance structure, PPIs are expected to move fast in making medicines available to people living with HIV/AIDS.. In practice, fast and effective action is proving to be difficult: funds for implementation of projects are often constrained, with implications for their functioning and the communities they are intended to serve.. Other risks have been recognised including strain on existing health infrastructure, inequity in delivery, and questions about accountability and responsiveness to the public.. Through working with academic institutions  ...   to medicines at the community and country levels, and to inform global data collection and policy.. HIV/AIDS.. Universal Access by 2010.. 10 challenges on the way.. By December 2005, approximately 1,3 million people in need of ART were actually receiving it.. If we are to achieve universal access to ART by 2010 all those engaged in implementation -at every level - must address the challenges.. HAI has developed a policy brief which highlights 10 challenges on the way to achieve universal access to ART by 2010.. Healthworkers, policy makers and ART users from 14 countries put forward these challenges during rapid appraisal assessments conducted by HAI, ITPC (International Treatment Preparedness Coalition) and the University of Amsterdam.. Now available, Spanish version of Universal Access: 10 Challenges on the way.. Country Working Papers.. Developments.. Articles.. Resources.. Archive..

    Original link path: /02_focus_c.htm
    Open archive

  • Title: ++ Health Action International Europe ++
    Descriptive info: Jacob van Lennepkade 334-T.. 1053 NJ Amsterdam.. Tel: +31 (0)20 683 3684.. Fax: +31 (0)20 685 5002.. E-mail:.. Annual Accounts (2005).. Mission Statement:.. Health Action International (HAI) is an independent, global network working to increase access to essential medicines and improve their rational use.. Essential Innovation..

    Original link path: /missionStatement.html
    Open archive

  • Title: ++ Health Action International Europe ++
    Descriptive info: Members Organisations.. Arab Resource Collective.. mawared.. Baby Milk Action.. babymilkaction.. BUKO Pharma Kampagne.. bukopharma.. de.. Club for Protection of Consumers Interests.. pateretaja-celvedis.. lv/english/club.. Consumers International.. consumersinternational.. Drug Info Moldova.. druginfomoldova.. Drug Utilization Research Group Public Organisation (Armenia).. Declaration de Berne.. evb.. ch/en.. DIFAM.. difaem.. EKPIZO.. ekpizo.. gr.. Farmaceuticos Mundi..  ...   KILEN.. kilen.. org/index.. La Revue Prescrire.. prescrire.. Medico International.. medico-international.. OXFAM UK.. oxfam.. Physicians for Social Responsibility.. lsv.. fi.. Polish Consumer Federation.. federacja-konsumentow.. pl/story.. php?story=164.. Projekt Farmaka.. farmaka.. be.. Reseau Medicaments et Developpement.. remed.. Swissmedic.. swissmedic.. ch.. Swiss Tropical Institute.. sti.. Verbraucherzentrale Bundesverband e.. V.. vzbv.. de/go.. Wemos.. wemos.. nl..

    Original link path: /HAIEuropeMemberOrganisations.htm
    Open archive

  • Title: Download
    Descriptive info: Please enter your e-mail address to download the publication.. It will not be shared with third parties, but it will help us gather feedback at a later stage.. E-Mail:.. I allow Health Action International to use my e-mail address for the purposes described in.. the disclaimer..

    Original link path: /10112010/?file=EN
    Open archive

  • Title: Download
    Original link path: /10112010/?file=FR
    (No additional info available in detailed archive for this subpage)

  • Title: Download
    Original link path: /10112010/?file=SP
    (No additional info available in detailed archive for this subpage)

  • Title: Download
    Original link path: /10112010/?file=RS
    (No additional info available in detailed archive for this subpage)

  • Title: ++ Health Action International Europe ++ [ Focus ]
    Descriptive info: IGWG2bis April 2008.. HAI-Europe statement.. African Civil Society coalition statement.. Indian Civil Society position.. World Health Organization.. HAI positions on the IGWG process.. HAI Europe members statements regarding health, access to medicine and innovation.. Innovation and access platform.. HAI Europe pressrelease 10 Nov 2007.. on the outcome of IGWG2 meeting 5-10 November 2007 in Geneva.. HAI  ...   Sep 2007.. HAI Africa submission.. Latin America Civil Society statement.. August 2007 (meeting organized by AIS Bolivia).. Berlin declaration.. for Innovation and Access to Essential Medicine.. 10-May-2007 initiated by Brot für die Welt, BUKO Pharma-Kampagne, medico international, Misereor (Germany); signed by HAI, MSF and others.. BUKO Pharma-Kampagne submission.. to the first WHO public hearing Nov 2006..

    Original link path: /02_focus_b-2007_2.htm
    Open archive


  • Archived pages: 58